{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:20:56Z","timestamp":1788351656344,"version":"build-2803163510"},"reference-count":70,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012069","name":"Hoyu Science Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Waksman Foundation of Japan","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"TELUMO Life Science Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ae0121013"],"award-info":[{"award-number":["JP21ae0121013"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JST SPRING","award":["JPMJSP2109"],"award-info":[{"award-number":["JPMJSP2109"]}]},{"name":"JSPS KAKENHI of Transformative Research Areas (A) 'Material Symbiosis\u2019","award":["21H05506"],"award-info":[{"award-number":["21H05506"]}]},{"name":"cSIMVA Vaccine Challenge Grants","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"the Early-Stage Research Grant for Medical and Pharmaceutical Sciences from the Future Medicine Education and Research Organization at Chiba University","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody therapeutics have revolutionized cancer treatment, but their use is increasingly associated with adverse events. Among these, anaphylaxis is particularly concerning due to its severity and unpredictability. Our previous studies demonstrated that repeated administration of anti-programmed death-ligand 1 antibodies to tumor-bearing mice induces antidrug antibodies (ADAs) and anaphylaxis. However, the specific characteristics of antibody therapeutics responsible for this effect and the underlying mechanism of ADA production remain poorly understood. This study aimed to identify the immunological and molecular determinants of ADA-associated anaphylaxis following antibody therapeutics in tumor-bearing hosts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CT26 and 4T1 tumor-bearing mice were repeatedly administered various therapeutic antibodies with differing affinities for Fc\u03b3 receptors (Fc\u03b3Rs). Anaphylaxis symptoms, body temperature, and mortality were evaluated. Serum ADA levels were quantified using ELISA. Antibody affinity for mouse Fc\u03b3R was determined using surface plasmon resonance. Antibody distribution in the spleen was assessed via immunofluorescence staining, and antibody glycosylation was analyzed by liquid chromatography-mass spectrometry. Immune cell populations were examined using flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Repeated administration of antibodies with high affinities for Fc\u03b3Rs to tumor-bearing mice induced robust ADA production and anaphylaxis, whereas antibodies with low affinities for Fc\u03b3Rs against the same target elicited only minimal ADA responses and did not trigger anaphylaxis. We identified this difference as being attributed to the ability of tumor-associated monocytic\u2013macrophage lineage cells to capture antibodies via Fc\u03b3R, altering antibody biodistribution in the spleen, thereby facilitating antigen presentation and activating humoral immunity. Pretreatment with Fc\u03b3R blocking antibodies attenuated this response, reducing anaphylaxis severity and improving survival. Analysis of clinical therapeutic antibodies also showed that those with a high affinity for Fc\u03b3Rs have a higher risk of inducing anaphylaxis, whereas neutralizing\/blocking antibodies with a low or no affinity for Fc\u03b3Rs have a lower risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High affinities for Fc\u03b3Rs were identified as a critical determinant of anaphylaxis and reveal a mechanism linking Fc\u03b3R-mediated antibody capture by tumor-associated myeloid cells to ADA induction. This contributes to the mechanistic foundation of AllergoOncology, an emerging interdisciplinary field exploring the interplay between cancer pathology and hypersensitivity reactions to therapeutic agents and providing insights for improving the safety and design of antibody therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013316","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:00:14Z","timestamp":1772632814000},"page":"e013316","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody therapeutics with high affinity for Fc\u03b3Rs exacerbate anaphylaxis via Fc\u03b3R-mediated capture by tumor-associated myeloid cells"],"prefix":"10.1136","volume":"14","author":[{"given":"Ruiheng","family":"Tang","sequence":"first","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizemaiti","family":"Aibai","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tamemoto","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riho","family":"Kume","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sato","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Abo","sequence":"additional","affiliation":[{"name":"Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science, Shinjuku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Higashi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science, Shinjuku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-8138","authenticated-orcid":false,"given":"Masato","family":"Kiyoshi","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Kanagawa Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Hashii","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Kanagawa Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Kanagawa Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Immunology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-0508","authenticated-orcid":false,"given":"Hiroto","family":"Hatakeyama","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"},{"name":"Center of Quantum Life Science for Structural Therapeutics, Chiba University, Chiba, Chiba Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026090204551432000_14.3.e013316.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.591"},{"key":"2026090204551432000_14.3.e013316.2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.t01-1-00001.x"},{"key":"2026090204551432000_14.3.e013316.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303"},{"key":"2026090204551432000_14.3.e013316.4","unstructured":"Tejedor-Alonso MA , Moro-Moro M , M\u00fagica-Garc\u00eda MV . Epidemiology of anaphylaxis: contributions from the last 10 years. J Investig Allergol Clin Immunol 2015;25."},{"key":"2026090204551432000_14.3.e013316.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.018"},{"key":"2026090204551432000_14.3.e013316.6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.lpm.2016.02.023","article-title":"Allergie et curares","volume":"45","author":"Chiriac","year":"2016","journal-title":"La Presse M\u00e9dicale"},{"key":"2026090204551432000_14.3.e013316.7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1081-1206(10)62318-6","article-title":"Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996)","volume":"87","author":"Cianferoni","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026090204551432000_14.3.e013316.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765747","article-title":"How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?","volume":"12","author":"Vultaggio","year":"2021","journal-title":"Front Immunol"},{"key":"2026090204551432000_14.3.e013316.9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2021.02.013","article-title":"Mechanisms of human drug-induced anaphylaxis","volume":"147","author":"Bruhns","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026090204551432000_14.3.e013316.10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.931"},{"key":"2026090204551432000_14.3.e013316.11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non-IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026090204551432000_14.3.e013316.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544742"},{"key":"2026090204551432000_14.3.e013316.13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1075114","article-title":"Repeated PD-1\/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer","volume":"5","author":"Mall","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026090204551432000_14.3.e013316.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005657","article-title":"Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor","volume":"10","author":"Arai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204551432000_14.3.e013316.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004"},{"key":"2026090204551432000_14.3.e013316.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2064"},{"key":"2026090204551432000_14.3.e013316.17","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13407"},{"key":"2026090204551432000_14.3.e013316.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37215-3","article-title":"Mechanism of antibody-specific deglycosylation and immune evasion by Streptococcal IgG-specific endoglycosidases","volume":"14","author":"Trastoy","year":"2023","journal-title":"Nat Commun"},{"key":"2026090204551432000_14.3.e013316.19","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13401"},{"key":"2026090204551432000_14.3.e013316.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.007"},{"key":"2026090204551432000_14.3.e013316.21","doi-asserted-by":"publisher","DOI":"10.1038\/nri3582"},{"key":"2026090204551432000_14.3.e013316.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1999.tb01372.x"},{"key":"2026090204551432000_14.3.e013316.23","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwv065"},{"key":"2026090204551432000_14.3.e013316.24","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12341"},{"key":"2026090204551432000_14.3.e013316.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108"},{"key":"2026090204551432000_14.3.e013316.26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168947","article-title":"The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026090204551432000_14.3.e013316.27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature New Biol"},{"key":"2026090204551432000_14.3.e013316.28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0191"},{"key":"2026090204551432000_14.3.e013316.29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059"},{"key":"2026090204551432000_14.3.e013316.30","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199811000-00012"},{"key":"2026090204551432000_14.3.e013316.31","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"2026090204551432000_14.3.e013316.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026090204551432000_14.3.e013316.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026090204551432000_14.3.e013316.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"2026090204551432000_14.3.e013316.35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026090204551432000_14.3.e013316.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"2026090204551432000_14.3.e013316.37","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"2026090204551432000_14.3.e013316.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2204"},{"key":"2026090204551432000_14.3.e013316.39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22370"},{"key":"2026090204551432000_14.3.e013316.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0116"},{"key":"2026090204551432000_14.3.e013316.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204551432000_14.3.e013316.42","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2026090204551432000_14.3.e013316.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0696"},{"key":"2026090204551432000_14.3.e013316.44","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-1538"},{"key":"2026090204551432000_14.3.e013316.45","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2026090204551432000_14.3.e013316.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2026090204551432000_14.3.e013316.47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2026090204551432000_14.3.e013316.48","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2654"},{"key":"2026090204551432000_14.3.e013316.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2982"},{"key":"2026090204551432000_14.3.e013316.50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"2026090204551432000_14.3.e013316.51","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2021.0068"},{"key":"2026090204551432000_14.3.e013316.52","doi-asserted-by":"publisher","DOI":"10.1038\/nri2206"},{"key":"2026090204551432000_14.3.e013316.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.07.009"},{"key":"2026090204551432000_14.3.e013316.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00637-8"},{"key":"2026090204551432000_14.3.e013316.55","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.882891","article-title":"Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin\u2019s Lymphoma-Enigma Variations","volume":"9","author":"Gilaberte Reyzabal","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026090204551432000_14.3.e013316.56","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1080\/10428194.2017.1306648","article-title":"Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients","volume":"58","author":"D\u2019Arena","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026090204551432000_14.3.e013316.57","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/ar1008","article-title":"Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis","volume":"5 Suppl 4","author":"Hainsworth","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"2026090204551432000_14.3.e013316.58","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MR1218-501R"},{"key":"2026090204551432000_14.3.e013316.59","doi-asserted-by":"crossref","first-page":"987151","DOI":"10.3389\/fimmu.2022.987151","article-title":"Role of N-Glycosylation in Fc\u03b3RIIIa interaction with IgG","volume":"13","author":"Van Coillie","year":"2022","journal-title":"Front Immunol"},{"key":"2026090204551432000_14.3.e013316.60","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature New Biol"},{"key":"2026090204551432000_14.3.e013316.61","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling","volume":"3","author":"Yofe","year":"2022","journal-title":"Nat Cancer"},{"key":"2026090204551432000_14.3.e013316.62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403014"},{"key":"2026090204551432000_14.3.e013316.63","article-title":"Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front Immunol"},{"key":"2026090204551432000_14.3.e013316.64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00408","article-title":"The Role of FcRn in Antigen Presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front Immunol"},{"key":"2026090204551432000_14.3.e013316.65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801717105"},{"key":"2026090204551432000_14.3.e013316.66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22199-8","article-title":"Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered Fc\u03b3Receptor IIIa-Immobilized Column","volume":"8","author":"Kiyoshi","year":"2018","journal-title":"Sci Rep"},{"key":"2026090204551432000_14.3.e013316.67","doi-asserted-by":"crossref","first-page":"116542","DOI":"10.1016\/j.jpba.2024.116542","article-title":"Multi-attribute method analysis of therapeutic monoclonal antibodies using an automated sample preparation system","volume":"253","author":"Hashii","year":"2025","journal-title":"J Pharm Biomed Anal"},{"key":"2026090204551432000_14.3.e013316.68","unstructured":"Food and Drug Administration (FDA) . FDA adverse event reporting system (faers) latest quarterly data files. Available: https:\/\/www.fda.gov\/drugs\/questions-andanswers-fdas-adverse-event-reporting-system-faers\/fda-adverse-eventreporting-system-faers-latest-quarterly-data-files [Accessed 30 Jan 2024]."},{"key":"2026090204551432000_14.3.e013316.69","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"2026090204551432000_14.3.e013316.70","unstructured":"National Institute of Health Sciences . Antibody drugs and Fc fusion proteins. Available: https:\/\/www.nihs.go.jp\/dbcb\/mabs.html [Accessed 17 Jul 2024]."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:55:35Z","timestamp":1788350135000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-013316"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013316","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}